Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.41 |
| ▸ | GGT1 | P19440 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33469 | 0.86 | HCAR2 (0.50) | HSD17B10KDM4EHPGDMAPTHCAR2 | |
| SCHEMBL21678774 | 0.86 | SMN1; SMN2 (0.50) | HSD17B10KDM4EHPGDMAPTLMNA | |
| SCHEMBL2332251 | 0.82 | HSD17B10 (0.61) | HSD17B10KDM4EHPGDMAPTLMNA | |
| SCHEMBL21678701 | 0.82 | HCRTR1 (0.49) | HSD17B10KDM4EHPGDMAPTLMNA | |
| SCHEMBL21678779 | 0.82 | IRAK4 (0.53) | HSD17B10KDM4EHPGDMAPTLMNA | |
| SCHEMBL7299840 | 0.80 | HPGD (0.51) | HSD17B10KDM4EHPGDMAPTLMNA | |
| SCHEMBL27652522 | 0.80 | KDM4E (0.86) | HSD17B10KDM4EHPGDMAPTLMNA | |
| SCHEMBL21678752 | 0.80 | KMT2A (0.47) | HSD17B10KDM4EHPGDMAPTLMNA | |
| Bissalicyl Fumarate SCHEMBL13351990 | 0.79 | KDM4E (1.00) | HSD17B10KDM4EHPGDMAPTLMNA | |
| SCHEMBL23357451 | 0.79 | ALDH1A1 (0.51) | HSD17B10KDM4EHPGDMAPTHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106983-A1 | SULFOXIDE AND SULFONE GLUCOKINASE ACTIVATORS AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-04-06 | — | — | US | disclosed |
| EP-4116290-A1 | PLATELET STORAGE METHODS AND COMPOSITIONS FOR SAME | Platefuse, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4013402-A1 | METHODS OF TREATING A SUBJECT WITH A CDC42-SPECIFIC INHIBITOR | Children's Hospital Medical Center (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3999053-A1 | METHOD OF TREATING NEOPLASTIC DISEASES WITH A CDC42-SPECIFIC INHIBITOR | Children's Hospital Medical Center (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220061312-A1 | PLATELET STORAGE METHODS AND COMPOSITIONS FOR SAME | PLATEFUSE, INC. | 2022-03-03 | — | — | US | disclosed |
| US-11172673-B2 | Platelet storage methods and compositions for same | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | disclosed |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2021034616-A1 | METHODS OF TREATING A SUBJECT WITH A CDC42-SPECIFIC INHIBITOR | CHILDREN' S HOSPITAL MEDICAL CENTER (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021011800-A1 | METHOD OF TREATING NEOPLASTIC DISEASES WITH A CDC42-SPECIFIC INHIBITOR | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2000023417-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023451-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023425-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023416-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| US-6054453-A | HYPOLIPIDEMIC, ANTIHYPERGLYCEMIC USES. | REDD'S RESEARCH FOUNDATION (IN) | 2000-04-25 | — | — | US | disclosed |
| EP-0958296-A1 | NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-11-24 | — | — | EP | disclosed |
| US-5985884-A | TREATMENT AND/OR PROPHYLAXIS OF DISEASES OR CONDITIONS IN WHICH INSULIN RESISTANCE IS THE UNDERLYING PATHOPHYSIOLOGICAL MECHANISM SUCH AS TYPE II DIABETES, IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDAEMIA, HYPERTENSION, CORONARY HEART DISEASE | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-11-16 | — | — | US | disclosed |
| WO-1999019313-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-22 | — | — | WO | disclosed |
| WO-1999008501-A2 | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-02-25 | — | — | WO | disclosed |
| WO-1997041097-A2 | NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220061312-A1 | PLATELET STORAGE METHODS AND COMPOSITIONS FOR SAME | RHOA, ARHGDIB, ARHGDIA | HSD17B10 3748/4885KDM4E 3760/4885HPGD 1710/4885 |
| US-11172673-B2 | Platelet storage methods and compositions for same | RHOA, ARHGDIB, ARHGDIA | HSD17B10 3748/4885KDM4E 3760/4885HPGD 1710/4885 |
| US-20230106983-A1 | SULFOXIDE AND SULFONE GLUCOKINASE ACTIVATORS AND METHODS OF USE THEREOF | GCK, GCKR, KHK | HSD17B10 1197/4885KDM4E 1647/4885HPGD 1293/4885 |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | PPARG, PPARA, PPARD | HSD17B10 290/4885KDM4E 3509/4885HPGD 313/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | HSD17B10 290/4885KDM4E 3509/4885HPGD 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.